Effect of a -Containing Acid-Resistant Microcapsule Formulation on Gut Microbiota: A Pilot Study.

Approximately 10 species are known to inhabit the human intestinal tract. Bifidobacteria have been reported to possess a variety of probiotic benefits. However, when bifidobacteria are consumed internally as probiotics, the bacteria are killed by gastric acid. Therefore, we developed acid-resistant microcapsules containing M-16V and BB536, which are unaffected by gastric acid, and evaluated whether the microcapsule formulation increased the amount of bifidobacteria in the stool after administration compared with the powder formulation. The results revealed no significant difference in the percentage or number of between before and after administration of the powder or microcapsule formulation in children. By contrast, the bacterial count of was significantly increased after microcapsule formulation administration (1.5 × 10 copies/g after administration versus 2.8 × 10 copies/g before administration, = 0.013). In addition, the increase in the bacterial count of in stools after administration of microcapsule formulation was approximately 1000-fold higher than that after powder formulation administration ( = 0.018). In conclusion, the results indicate that the microcapsule formulation is efficiently transferred to the large intestine without the adverse effects of gastric acidity in children.